Tanshinone IIA attenuates ovalbumin-induced airway inflammation and hyperresponsiveness in a murine model of asthma

• Main Authors: Shi-Biao Wang, Xiao-Feng Guo, Bin Weng, Su-Ping Tang, Hui-Jie Zhang
• Format: Article
• Language: English
• Published: Mashhad University of Medical Sciences 2019-02-01
• Series: Iranian Journal of Basic Medical Sciences
• Subjects: Asthma; Inflammation; Nuclear factor-κB; Oxidative stress; Tanshinone IIA
• Online Access: http://ijbms.mums.ac.ir/article_12013_a34ad9a46edf2b1fb45dbefd20b0c5ff.pdf

Objective(s): Tanshinone IIA (T. IIA), one of the most pharmacologically active components extracted from Salviae miltiorrhiza, has anti-inflammatory and antioxidant features. The aim of the present study is to investigate the benefit of T. IIA on asthma using a murine model of asthma induced by ovalbumin (OVA). Materials and Methods: Male BALB/c mice were used in the present study. The mice were sensitized by OVA intraperitoneal injection on days 0 and 14, and received aerosolized OVA challenge for 30 min daily on days 21-23Results: T. T. IIA (10 mg/kg twice daily) intraperitoneal injection was performed on days 18-23. Results: Treatment of T. IIA reduced the levels of interleukin (IL)-4, IL-5, and IL-13 in bronchoalveolar lavage fluid (BALF) (PConclusion: T. IIA inhibits OVA-induced airway inflammation and hyperresponsiveness. T. IIA is a potential therapeutic agent for asthma.